A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

This Phase 2 study is testing a combination of subcutaneous blinatumomab (an injectable immunotherapy) with low-intensity chemotherapy in older adults or medically unfit patients newly diagnosed with a type of leukemia called B-cell acute lymphoblastic leukemia (B-ALL) that does not have the Philadelphia chromosome. **You may be eligible if...** - You are 60 or older with newly diagnosed Ph-negative B-ALL, OR - You are between 18 and 59 with Ph-negative B-ALL but are not fit for intensive chemotherapy due to a significant health condition (e.g., heart or lung problems) - You have adequate organ function (kidney, liver) - You are willing to use contraception during and after treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are HIV-positive - You have active, untreated hepatitis B or C - You have Philadelphia chromosome-positive leukemia - You have a serious neurological or psychiatric condition (including prior severe reactions from CAR-T therapy) - You have had previous treatment with blinatumomab - You have active autoimmune disease - Your heart pumping function is below 40% Talk to your doctor to see if this trial is right for you.